SWITZERLAND – Angelini Pharma acquires Swiss company Arvelle Therapeutics.
Italian company Angelini Pharma, part of Angelini Group, has entered into an agreement to acquire the Swiss pharmaceutical company Arvelle Therapeutics, responsible for the development and marketing in Europe of the new anti-seizure drug cenobamate. The agreement is worth over 950 million euros and, as emphasised by the top management of the Italian company, is the largest investment ever in Angelini’s history. As a result of the acquisition, the company will become the exclusive licensee in Europe of the anti-seizure drug, which has already been approved by the US FDA and is expected to be authorised by the European Medicines Agency in the forthcoming months.
